Hints and tips:
Related Topics
...As well as proceeds from its Covid products, Pfizer has also benefited from the spin-off of its Upjohn generics business, which combined with Mylan to form Viatris in late 2020....
...In 2020, Pfizer spun off its generics business Upjohn, combining it with Mylan to form Viatris, while Johnson & Johnson, GSK, Pfizer and Novartis have all shed their consumer health businesses selling over-the-counter...
...Gilead told the FT that in India the price of the drug and the terms of supply are negotiated by the US company Viatris, previously also known as Mylan, which holds the marketing authorisation for AmBisome...
...Results and forecasts exclude its Upjohn unit, as Pfizer closed the transaction to merge the generics business with Mylan during the quarter....
...The US District Court for the Northern District of West Virginia decided in favour of AstraZeneca in litigation against Mylan Pharmaceuticals and Kindeva, the company said....
...Mylan, a US-based generics maker, has restarted production of hydroxychloroquine at its West Virginia plant and is looking to increase manufacturing outside of the US too....
...In mid-afternoon trading in New York, shares in Mylan, which is in the process of merging with Pfizer’s generics business Upjohn, were up 2.6 per cent to $22.83....
...Drugs group Mylan does not manufacture multiple sclerosis treatment Copaxone as incorrectly stated in a Lex note on July 30....
...Manufacturers such as Teva, Mylan, and Novartis have promised to increase supply — and some are giving the drug away for free....
...The deal with Mylan is similar. Here, however, Pfizer is spinning off Upjohn and then combining it with all of Mylan....
...Teva, Mylan and others in the lawsuits have denied wrongdoing....
...The deal comes after a near-50 per cent drop in Mylan shares over the past year as sales slowed. Heather Bresch will retire after eight years as Mylan chief executive when the transaction closes....
...The plans would also see Mylan’s chief executive Heather Bresch depart, after leading the company for seven years....
...For all Mylan stakeholders, half a decade seems like a lifetime ago....
...Higher-rated corporate debt was also hit, with bonds from carmaker Ford, drugmaker Mylan and cable television operator ViacomCBS all sliding in value....
...Drugmakers, including Novartis, Sanofi, Teva and Mylan, have said they would ramp up production of the drug and distribute it for compassionate use....
...Plus, Pfizer reaches a deal to combine its Upjohn unit with generics drugmaker Mylan, Beyond Meat announces a stock sale and Sterling tumbles to its lowest level in two and a half years on Monday as market...
...and spinning off their consumer health divisions, which sell over-the-counter products, while Pfizer is in the process of trying to combine its generics business Upjohn with the large generics drugmaker Mylan...
...To stave off shortages, generic drugmakers like Mylan are ramping up production....
...Shares in Mylan fell 10.2 per cent to $27.50 in after hours trading in New York....
...Lex took a look at the spectacular share price drop for US drugs company Mylan. It betrayed a loss of confidence in Mylan’s top bosses, we said. But there is a broader issue at play....
...positive market-movers on that day -- January 2 -- via Bloomberg: Advanced Micro Devices: +7.06%General Electric: +6.90%Western Digital: +4.21%Wynn Resorts: +3.41%Occidental Petroleum: +3.32%MSCI: +3.05%Mylan...
...Shares in Biogen jumped as much as 32 per cent after the US biotech company won a patent battle against the generic drugmaker Mylan over its bestselling medicine for multiple sclerosis....
...Large generics manufacturers including Mylan and Teva Pharmaceutical would not comment on potential supply chain problems....
...Investors will seek updates on Pfizer’s deal with Mylan on Thursday, while AbbVie’s acquisition of Allergan, which is nearing completion, will be in focus on Friday....
International Edition